Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics Inc (NQ: IOVA )

6.110 -0.040 (-0.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,505,571
Open 6.140
Bid (Size) 6.080 (2)
Ask (Size) 6.150 (6)
Prev. Close 6.150
Today's Range 6.030 - 6.250
52wk Range 5.385 - 18.73
Shares Outstanding 224,238,882
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Shares of Iovance Biotherapeutics Jumped Monday
The company filed a Biologics License Application to the FDA for its lead therapy. 
Via The Motley Fool
Why Iovance Biotherapeutics Shares Are Trading Higher Today
Iovance Biotherapeutics (NASDAQ: IOVA) shares are trading higher on Monday after the company completed its Biologics License Application submission for lifileucel. 
Via Benzinga

Performance

YTD
N/A
N/A
1 Month
-16.30%
-16.30%
3 Month
-4.38%
-4.38%
6 Month
-36.22%
-36.22%
1 Year
-63.30%
-63.30%

More News

Read More
Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Analyst Expectations for Iovance Biotherapeutics's Future
Via Benzinga
Expert Ratings for Iovance Biotherapeutics
Via Benzinga
The Latest Analyst Ratings for Iovance Biotherapeutics
Via Benzinga
What 6 Analyst Ratings Have To Say About Iovance Biotherapeutics
Via Benzinga
Why Motorsport Games Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
First Republic Bank, KeyCorp And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Via Benzinga
Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
Via Benzinga
American Express, Visa And Other Big Stocks Moving Higher In Friday's Pre-Market Session
Via Benzinga
Why Iovance Biotherapeutics Stock Soared 12% Higher Today
Via The Motley Fool
Iovance Biotherapeutics Acquires Clinigen's IL-2 Product For Upfront £166.7M
Via Benzinga
Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Why Is Iovance Biotherapeutics (IOVA) Stock Soaring 20% Today?
Via InvestorPlace
Why Iovance Biotherapeutics Shares Are Trading Higher By Around 19%? Here Are 40 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
US Stocks Start Week On Lower Note; Dow Tumbles 250 Points
Via Benzinga
Iovance Biotherapeutics Stock Is Surging: Here's Why
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
$65 Million Bet On Iovance Biotherapeutics? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.